Search clinical trials for: GSK2110183

Total 9 results

GlaxoSmithKline

Completed

Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

Cancer

Australia
GlaxoSmithKline

Completed

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

Langerhans Cell Histiocytosis

United States
Accenture

Completed

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Hematologic Malignancies

Korea, Republic of, Australia, Canada
Novartis Pharmaceuticals

Completed

Continuation Study of the Oral AKT Inhibitor GSK2110183

Cancer

Australia, United States, Ireland, Canada, Korea, Republic of
University Health Network, Toronto
Novartis

Completed

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

Canada
GlaxoSmithKline

Withdrawn

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Cancer

Australia
GlaxoSmithKline

Completed

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Cancer

United States
Novartis

Completed

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (PKB115125)

Multiple Myeloma

Canada, United States, Australia, Taiwan, Ireland
Accenture

Completed

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

Australia, Russian Federation, United Kingdom

3

Subscribe